Published • loading... • Updated
HEALEY ALS Platform Trial Regimen I Enrolment Completed - Topline Results for NUZ-001 Accelerated to Q2 CY2027
- Neurizon Therapeutics completed enrollment for Regimen I of the Phase 2/3 HEALEY ALS Platform Trial testing NUZ-001 for amyotrophic lateral sclerosis .
- Regimen I enrolled 240 participants in under five months, the fastest for the HEALEY ALS Platform Trial after increasing the sample size due to strong recruitment.
- Neurizon expects to report topline efficacy and safety results by late Q2 CY2027, earlier than initially planned.
- The completion of enrollment reduces risks for Neurizon's clinical program and reflects strong recruitment and effective trial execution, with patients continuing through a 36-week randomized controlled trial before an extension phase.
Insights by Ground AI
40 Articles
40 Articles
HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027
250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so farAnticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027Completion…
·Pennsylvania, United States
Read Full ArticleNeurizon completes enrolment in pivotal ALS trial, topline results brought forward
The final participant has completed their baseline visit and started treatment, completing enrolment into Regimen I. ... The post Neurizon completes enrolment in pivotal ALS trial, topline results brought forward appeared first on Stockhead.
Coverage Details
Total News Sources40
Leaning Left3Leaning Right6Center25Last UpdatedBias Distribution73% Center
Bias Distribution
- 73% of the sources are Center
73% Center
C 73%
R 18%
Factuality
To view factuality data please Upgrade to Premium
